Uses of Primula family plant extracts

Primulaceae plant extracts are used to create antifungal and antioxidant compositions that promote gene expression, addressing the need for natural preservatives and improving the quality of food, beverages, and cosmetics.

JP7595973B2Active Publication Date: 2024-12-09SAISHUNKAN SEIYAKUSHO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023125236
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-08-01
Publication Date
2024-12-09
Estimated Expiration
2039-09-11

AI Technical Summary

Technical Problem

There is a high demand for antifungal agents that are free from chemically synthesized preservatives, and existing technologies have not recognized the antifungal effects of Primulaceae plant extracts.

Method used

Extracts from Primulaceae plants, such as Sorghum, are used to create antifungal, antioxidant, and hyaluronic acid synthase gene expression promoters, promoting genes like SOD1, FN3K, NRF2, and HAS2, which are incorporated into compositions for various applications.

Benefits of technology

The extracts provide effective antifungal, antioxidant, and gene expression promoting effects, suitable for use in food, beverages, cosmetics, quasi-drugs, and pharmaceuticals, enhancing their quality and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595973000008
    Figure 0007595973000008
  • Figure 0007595973000009
    Figure 0007595973000009
  • Figure 0007595973000001
    Figure 0007595973000001
Patent Text Reader

Abstract

To provide antifungal agents in one embodiment, and to provide novel uses of the extract of Primulaceae in another embodiment.SOLUTION: In one embodiment, the present invention relates to an antifungal agent, an antioxidant, a deglycation agent, a hyaluronan synthase gene expression promoter, or an expression promoter for at least one gene selected from the group consisting of SOD1, FN3K, NRF2, and HAS2, which contain an extract of Primulaceae. In another embodiment, the present invention relates to an extract of Primulaceae, or an antifungal agent, an antioxidant, a deglycation agent, or a composition containing a gene expression promoter, which are described herein.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antifungal agent, an antioxidant, a deglycosylating agent, or an agent for promoting the expression of a hyaluronic acid synthase gene, which contains an extract of a plant of the Primulaceae family, or a cosmetic composition containing these, etc. [Background technology]

[0002] Yeasts and molds cause spoilage of cosmetics, food and beverages, medicines, etc. Although preservatives with antifungal activity can be used to inhibit spoilage, there is a high demand from consumers for products that do not contain chemically synthesized preservatives.

[0003] Patent Document 1 describes an insect repellent that contains at least an extract of Ryukyuai leaves and an extract of Sorghum gracilis leaves. However, it has not been known that extracts of Primulaceae plants have antifungal effects or the like. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2001-348305 A Summary of the Invention [Problem to be solved by the invention]

[0005] In one embodiment, the present invention aims to provide an antifungal agent. In another embodiment, the present invention aims to provide a novel use of an extract of a plant of the Primulaceae family. [Means for solving the problem]

[0006] The present inventor has found that the extract of Primulaceae plant has antifungal activity.The present inventor has also found that the extract of Primulaceae plant can have not only antifungal activity but also antioxidant activity, deglycation activity, hyaluronic acid synthase gene expression promoting activity, and at least one gene expression promoting activity selected from the group consisting of SOD1, FN3K, NRF2, and HAS2, and has completed the present invention.

[0007] The present invention includes the following aspects. (1) A composition for promoting gene expression, comprising an extract of a plant of the genus Lycoris, and promoting the expression of a target hyaluronic acid synthase gene. (2) The composition for promoting gene expression described in (1), wherein the hyaluronic acid synthase gene includes HAS2 and promotes hyaluronic acid synthesis in a subject. (3) A composition for promoting gene expression described in (1) or (2), which further promotes the expression of a gene related to the antioxidant effect of a subject and has an antioxidant promoting effect in a subject. (4) The composition for promoting gene expression described in (3), wherein the gene related to the antioxidant effect is SOD1 or NRF2. (5) A composition for promoting gene expression described in any one of (1) to (4), which further promotes expression of a gene related to deglycation in a subject and has a deglycation-promoting effect in a subject. (6) The gene related to the deglycosylation function is FN 3 The composition for promoting gene expression according to (5), wherein the compound is K. (7) The composition for promoting gene expression described in any one of (1) to (6), wherein the plant of the genus Lycoris is Sclerotium. Effect of the Invention

[0008] The present invention provides an antifungal agent, an antioxidant, a deglycosylating agent, an expression promoter of a hyaluronic acid synthase gene, and an expression promoter of at least one gene selected from the group consisting of SOD1, FN3K, NRF2, and HAS2, etc. The present invention is applicable to, for example, foods and beverages, cosmetics, quasi-drugs, medicines, and agricultural chemicals. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 shows the gene expression levels of SOD1 (A), FN3K (B), and NRF2 (C) in HaCaT cells treated with Sorghum extract. [Diagram 2] Figure 2 shows the gene expression levels of NRF2 and HAS2 in fibroblasts treated with Sorghum extract, respectively (a representative example of two tests is shown). As shown in Figures 2A and B, the gene expression levels of NRF2 and HAS2 were increased by treatment with Sorghum extract. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] As used herein, examples of "Primulaceae plants" include, but are not limited to, the genera Lysimachia, Maesa, Androsace, Primula, Anagallis, Ardisia, and Cyclamen, and may be, for example, plants belonging to the genus Lysimachia or Maesa. Examples of plants of the genus Lysimachia include Lysimachia sikokiana, Lysimachia thyrsiflora, Lysimachia japonica, Lysimachia fortunei, Lysimachia clethroides, Lysimachia barystachys, and Lysimachia europaea, and examples of plants of the genus Maesa include Maesa japonica and Maesa montana A. DC. The Primulaceae plant may be, for example, Maesa sikokiana or Maesa thyrsiflora.

[0011] The part and form of the Primulaceae plant used to obtain the extract are not limited. For example, the whole plant, above-ground or underground parts of the Primulaceae plant, such as leaves and / or stems, can be used. The Primulaceae plant may be used as is to obtain the extract, but the extract may also be obtained using a processed product, such as a dried, crushed, sterilized or disinfected, heated, and / or cooled product, such as a dried powder.

[0012] The extract can be obtained by any extraction method. Extraction from a primrose plant may be carried out by adding a solvent to the above-mentioned primrose plant or a processed product thereof, and allowing the mixture to stand, stir or shake.

[0013] The solvent for extraction (extraction solvent) is not particularly limited, but a solvent containing alcohol and / or water can be used, and may be, for example, water, alcohol, or a mixed solvent of water and alcohol (hydrous alcohol). Water may be any water, such as pure water, ultrapure water, demineralized water, sterilized water, distilled water, and tap water. The solvent containing water may be a buffer solution, physiological saline, dilute acid, dilute alkali, and the like. The alcohol may be a monohydric alcohol or a polyhydric alcohol (e.g., a dihydric alcohol or an alcohol having three or more hydric groups). The monohydric alcohol may be, for example, ethanol, methanol, propyl alcohol, butyl alcohol, isobutyl alcohol, benzyl alcohol, and the like. The polyhydric alcohol may be, for example, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, and the like. In one embodiment, the solvent is preferably a solvent that is formulated and acceptable in the field of medicine or cosmetics, and preferably contains, for example, alcohol or water that is formulated and acceptable in the field of medicine or cosmetics. Alternatively, when the solvent is changed by solvent replacement or the like after extraction, a solvent other than that formulated and acceptable in the field of medicine or cosmetics may be used for extraction. For example, the solvent may include water, an alcohol (eg, ethanol, methanol, or 1,3-butylene glycol), or a hydroalcohol (a mixed solvent of water and alcohol).

[0014] In one embodiment, it is preferable to use a solvent having an alcohol concentration of 10 to 90 w / w%, for example, 30 to 80 w / w% or 50 to 70 w / w%, for extraction. For example, a solvent containing ethanol, methanol, or 1,3-butylene glycol at a concentration of 30 to 80 w / w% or 50 to 70 w / w% can be used for extraction.

[0015] The amount of the solvent for extraction added to a Primulaceae plant or a processed product thereof is not limited to the following, and may be, for example, 0.1 to 1000 times, 10 to 100 times, 25 to 75 times, or 40 to 60 times (weight ratio) the raw material Primulaceae plant or a processed product thereof (dry weight).

[0016] The extraction may be performed at, but is not limited to, 10 to 80° C., 20 to 60° C., 20 to 40° C., or at room temperature. The extraction time is not limited to, but may be, for example, several hours to several months, 12 hours to 1 month, 1 day to 14 days, or 2 days to 7 days.

[0017] In one embodiment, the extract of a Primulaceae plant of the present invention is an extract with the above-mentioned solvent obtained according to the above-mentioned extraction method, wherein an extract with a water-based solvent is an aqueous extract, an extract with an alcohol-based solvent is an alcoholic extract, and an extract with a hydroalcohol-based solvent is an aqueous-alcoholic extract.

[0018] The extract of a Primulaceae plant obtained as described above may be used as it is (raw extract solution) or after one or more treatments such as concentration, dilution, solvent exchange, drying, sterilization / disinfection, deodorization / decolorization, or purification by filtration (e.g., microfiltration) or centrifugation. The purification method is not particularly limited, and may be purified by filtration using a filter such as a membrane filter. In one embodiment, the extract of a Primulaceae plant may be dried and then dissolved or suspended in the same or another solvent. The solvent used in this case may be as described above for the extraction solvent, or may be another solvent such as dimethyl sulfoxide (DMSO).

[0019] In one aspect, the present invention relates to an antifungal agent comprising or consisting of an extract of a Primulaceae plant. In this specification, the term "antifungal agent" includes agents having bactericidal, sterilizing, or bacteriostatic effects on fungi. The types of fungi that can be treated with the antifungal agent are not limited, and examples thereof include fungi from the Trichocomaceae family, such as fungi from the genera Penicillium, Aspergillus, and Talaromyces; and fungi from the Saccharomycetaceae family, such as fungi from the genera Candida, Pichia, Saccharomyces, Zygosaccharomyces, Kluyveromyces, and Komagataella. Examples of fungi of the genus Penicillium include Penicillium paneum, Penicillium chrysogenum, Penicillium oxalicum, Penicillium citrinum, Penicillium expansum, Penicillium roqueforti, Penicillium digitatum, and Penicillium italicum, examples of fungi of the genus Pichia include Pichia anomala, Pichia membranaefaciens, Pichia pastoris, and Pichia kluyveri, and examples of fungi of the genus Candida include Candida albicans, Candida parapsilosis, Candida famata, and Candida glabrata. The fungi that are the target of the antifungal agent of the present invention may be, for example, at least one of Penicillium paneum, Pichia anomala, and Candida albicans.

[0020] In one aspect, the present invention relates to an antioxidant comprising or consisting of an extract of a plant of the Primulaceae family. The term "antioxidant" refers to an agent having an antioxidant effect (e.g., in a subject or in tissues or cells derived from a subject). In one embodiment, the antioxidant effect includes promoting the expression of a protein having an antioxidant effect and / or a gene thereof. An example of a protein having an antioxidant effect is a protein that inhibits the oxidation of superoxide anion (O2 - Examples of antioxidants include superoxide dismutase (SOD), an oxidoreductase that dismutates oxidative stress to oxygen and hydrogen peroxide, such as SOD1, SOD2, and SOD3, and NRF2 (NF-E2 Related Factor 2), a transcription factor that can control oxidative stress adaptation responses. NRF2 is known to control cellular adaptation to oxidants and electrophiles by inducing antioxidant and detoxification genes in response to redox stress (see, for example, Hayes JD and McMahon M., 2009, Trends Biochem. Sci.,34, 176-188). The method for measuring the antioxidant effect is not limited. For example, the antioxidant effect can be measured by measuring the expression level of genes and / or proteins of SOD2 and / or NRF2, such as SOD2, for example, by measuring the expression level of genes as described in the Examples.

[0021] In one aspect, the present invention relates to a deglycating agent comprising or consisting of an extract of a Primulaceae plant. As used herein, the term "deglycating agent" refers to an agent that has a deglycation effect, for example, reducing the amount of advanced glycation end products (AGEs) produced (e.g., in a subject or tissues or cells derived from a subject). In one embodiment, the deglycating effect includes promoting the expression of a protein having a deglycating effect and / or its gene. An example of a protein having a deglycating effect is FN3K (fructosamine 3-kinase), an enzyme that metabolizes AGEs. It is known that FN3K catalyzes the phosphorylation of fructosamine formed by glycation, and the phosphorylation of fructosamine can result in deglycation of glycated proteins (see, for example, Ghislain Delpierre et al., Biochem. J., 2002, 1, 365, 801-808; JP 2014-76957 A; and Ryoji Nagai et al., Anti-Aging Medicine, 7(10), 112-119, 2010). The method for measuring the deglycation effect is not limited. For example, the deglycation effect can be measured by measuring the expression level of the FN3K gene and / or protein, for example, by measuring the expression level of the gene as described in the Examples.

[0022] In one aspect, the present invention relates to an expression promoter for hyaluronic acid synthase gene comprising or consisting of an extract of a Primulaceae plant. The term "expression promoter for hyaluronic acid synthase gene" refers to a drug that promotes the expression of hyaluronic acid synthase gene (for example, in a subject or tissue or cell derived from a subject). Hyaluronic acid is a type of linear glycosaminoglycan (mucopolysaccharide), which is present in large amounts in the skin and is considered to prevent dryness due to its ability to retain moisture, and to be deeply involved in the moisture, firmness, elasticity, wrinkles, sagging, etc. of the skin. Examples of mammalian hyaluronic acid synthase include HAS (hyaluronan synthase) 1, HAS2, and HAS3. There is no limitation on the method for measuring the expression promotion effect of hyaluronic acid synthase gene. For example, as described in the Examples, the expression promotion effect of hyaluronic acid synthase gene can be measured by measuring the expression level of hyaluronic acid synthase gene such as HAS2.

[0023] In one aspect, the present invention relates to an agent for promoting the expression of at least one gene selected from the group consisting of SOD1, FN3K, NRF2, and HAS2, comprising or consisting of an extract of a Primulaceae plant. The method for measuring the expression promoting effect of a gene selected from the group consisting of SOD1, FN3K, NRF2, and HAS2 is not limited. For example, the expression levels of these genes can be measured as described in the Examples.

[0024] In one aspect, the present invention relates to a composition comprising an extract of a Primulaceae plant (e.g., as an active ingredient). In one aspect, the present invention relates to a composition comprising an antifungal agent, an antioxidant, a deglycosylating agent, or a gene expression promoter described herein (e.g., as an active ingredient). The type of the composition is not limited, and may be any of a food or drink, a cosmetic, a quasi-drug, a pharmaceutical composition, and an agricultural chemical composition.

[0025] In this specification, the term "quasi-drug" refers to a product defined by the Pharmaceutical and Medical Device Act that has a milder effect on the human body than pharmaceuticals. Examples of quasi-drugs include, but are not limited to, supplements and medicated cosmetics.

[0026] In addition to the above-mentioned components, the composition of the present invention may contain one or more other components, such as a pharma- ceutically acceptable carrier or solvent, etc. Examples of pharma- ceutically acceptable carriers include surfactants, pH adjusters, stabilizers, excipients, vehicles, preservatives, diluents, isotonicity agents, buffers, and other additives, and examples of solvents include sterilized water, physiological saline, and buffer solutions (including phosphate buffers, etc.).

[0027] The composition of the present invention can be formulated in principle by a method known in the art. For example, it can be formulated by the method described in Remington's Pharmaceutical Sciences (Merck Publishing Co., Easton, Pa.). The specific formulation method varies depending on the administration method. The administration method is roughly divided into oral administration and parenteral administration, and the administration method can be appropriately selected.

[0028] The form of the composition of the present invention is not limited. For example, it may be any of liquid, wettable powder, emulsion, powder, suspension, granule, capsule, and spray. The composition of the present invention can be used, for example, as a deodorant or deodorant spray.

[0029] The content of the active ingredient in the composition of the present invention may be an amount that allows the active ingredient to reach the target site in a single administration and that causes little or no harmful side effects to the subject to which it is applied. Such a content varies depending on the type of active ingredient, the dosage form of the composition, the administration method, etc., and can be appropriately determined by a person skilled in the art. For example, the final concentration of the extract in the composition may be 0.1 ppm or more, 1 ppm or more, 10 ppm or more, 50 ppm or more, 10% or less, 2% or less, 1% or less, 5000 ppm or less, 1000 ppm or less, or 200 ppm or less, for example, 0.1 ppm to 10% or 50 ppm to 2%.

[0030] When the compositions of the present invention are administered to a subject, the species of interest may include, but are not limited to, mammals, e.g., primates such as humans and chimpanzees, laboratory animals such as rats and mice, livestock animals such as pigs, cows, horses, sheep, and goats, and companion animals such as dogs and cats, e.g., humans.

[0031] Since the extract of the Primulaceae plant of the present invention may have antioxidant, deglycosylation, and / or promotion of the synthesis of hyaluronic acid synthase genes, the composition of the present invention, e.g., a cosmetic composition, can be used for anti-aging of the skin (e.g., improvement, prevention, and / or treatment of at least one symptom selected from the group consisting of wrinkles, sagging skin, loss of firmness and / or elasticity, and rough skin).

[0032] In one aspect, the present invention relates to a method for producing an antifungal agent, an antioxidant agent, a deglycation agent, or a gene expression promoter, or a composition as described herein, comprising obtaining an extract of a Primulaceae plant and optionally adding other ingredients (e.g., a pharma- ceutically acceptable carrier as described herein) to the extract. Details of the method for producing the extract or composition are as described herein.

[0033] The present invention will be described in more detail below with reference to examples, but the scope of the present invention is not limited to these examples. EXAMPLES

[0034] Example 1: Antibacterial activity of Sorghum extract Materials and Methods Preparation of Sorghum Extract Extracts were prepared by extracting the dried powder of the aerial parts of Sorghum with multiple solvents. Specifically, 500 mg of dried powder of the aerial parts of Sorghum was mixed with 25 ml of 50% EtOH, extracted for 2 days, concentrated to dryness, and dissolved in DMSO to obtain Extract 1. 500 mg of dried powder of the aerial parts of Sorghum was mixed with 25 ml of methanol (FUJIFILM Wako Pure Chemical Industries, hereafter also referred to as MeOH), extracted for 2 days, concentrated to dryness, and dissolved in DMSO to obtain Extract 2. 25 ml of 70% 1,3-butylene glycol (cosmetic concentrated glycerin: Sakamoto Yakuhin Kogyo Co., Ltd., hereafter also referred to as BG) was added to 2.5 g of dried powder of the aerial parts of Sorghum was mixed with 25 ml of BG, extracted for 1 week to obtain Extract 3. These extracts were subjected to a bacterial growth inhibition test by the following method.

[0035] Evaluation of the activity of Sorghum extract against Penicillium paneum (fungal growth inhibition test) Penicillium paneum wild-type strain (hereinafter referred to as Pp, obtained from Saishunkan Pharmaceutical Co., Ltd.) was cultured on a fungal agar medium (Sabouraud-Dextrose Agar with Lecithin & Polysorbate 80 DAIGO: Nippon Pharmaceutical Co., Ltd., composition: Dextrose 40.0 g / L, Peptone (meat & casein) 10.0 g / L, Agar 15.0 g / L, Lecithin (ASOLECTIN) 1.0 g / L, Polysorbate 80 7.0 g / L, final pH 5.4-5.8). Mature spores were collected using a sterile cotton swab and suspended in physiological saline containing 0.075% Polyoxyethylene (20) Sorbitan Monooleate (FUJIFILM Wako Pure Chemical Co., Ltd.) at 2 × 10 7 The solution was adjusted to cfu / ml and filtered through a sterile gauze folded in four (Hayashi Eizai Co., Ltd.) to obtain a bacterial solution.

[0036] Liquid medium for fungi (Difco TMA mixed liquid medium was prepared by adding 100 μl of the prepared bacterial solution to 14.9 ml of a mixture of Sabouraud Dextrose Broth (Becton, Dickinson and Company Sparks, MD 21152, composition: Peptic Digest of Animal Tissue 5.0 g, Pancreatic Digest of Casein 5.0 g, Dextrose 20.0 g) and sterile water. The mixed liquid medium was placed in a 96-well plate (96 Well Cell Culture Plate Sterile, Non-pyrogenic Polystyrene: True Line) and filtered with a filter (Steradisc 25 0.2 μm γ-ray sterile). <s-2502>The extracts were mixed to the specified concentrations, with the extracts filtered through a filter paper filter (Kuraray Industries, Inc.). The final concentrations of the extracts were 200 ppm or 100 ppm for extract 1, 200 ppm, 100 ppm, or 50 ppm for extract 2, and 2% or 1% for extract 3. The mixtures were cultured at 25°C for 72 hours, and the presence or absence of germination was confirmed visually and under a microscope (OLYMPUS IX73) (bacterial growth inhibition test), and compared with a negative control (NC) to which no extract was added.

[0037] (result) The results of the activity evaluation against Penicillium paneum are shown in Tables 1 and 2 below (representative results are shown from n=2 tests). The evaluation criteria were 4: no growth observed by visual and microscopic observation (-), no growth observed by visual observation (±), more suppressed than NC by visual observation (+), and turbid to the same extent as NC (++).

[0038] [Table 1]

[0039] [Table 2]

[0040] Example 2: Activity of Sorghum Extract Against Other Fungi Materials and Methods Extract 2 prepared in Example 1 was used to examine its antibacterial spectrum. The test bacteria used were Candida albicans NBRC1594 strain (hereinafter also referred to as Ca, obtained from NBRC) and Pichia anomala wild type strain (hereinafter also referred to as Pichia, obtained from Saishunkan Pharmaceutical Co., Ltd.). Ca or Pichia cultured on the same fungal agar medium as in Example 1 was collected with a platinum loop and suspended in physiological saline. Ca was 2 × 10 7 cfu / ml, Pichia was 2×10 6 The final concentration of Extract 2 was adjusted to 400 ppm, 200 ppm, or 100 ppm, and a bacterial growth inhibition test was carried out in the same manner as in Example 1.

[0041] (result) The results of the activity evaluation of Extract 2 against Candida albicans and Pichia anomala are shown in Table 3 below (a representative result is shown out of n=2 tests). The evaluation criteria were the same as those in Example 1.

[0042] [Table 3]

[0043] Example 3: Examination of parts of sorghum Materials and Methods 25 ml of MeOH was added to 500 mg of dried powder of Sorghum leaf, extracted for 2 days, concentrated and dried, and dissolved in DMSO to prepare Sorghum leaf extract. Sorghum stem extract was also prepared from dried powder of Sorghum stem in the same manner. A bacterial growth inhibition test was carried out in the same manner as in Example 1, using Pp as the test bacterium. The final concentrations of the extracts were 100 ppm or 50 ppm for Sorghum leaf extract and 500 ppm or 250 ppm for Sorghum stem extract.

[0044] (result) The results of the activity evaluation of sorghum leaf extract and sorghum stem extract against Penicillium paneum are shown in Tables 4 and 5 below (a representative result is shown out of n=2 tests).

[0045] [Table 4]

[0046] [Table 5]

[0047] Example 4: Study of Izusenryo Extract Materials and Methods Preparation of Izusamenryou extract 25 ml of methanol (Fujifilm Wako Pure Chemical Industries, Ltd., hereafter referred to as MeOH) was added to 500 mg of dried aboveground parts of Izusenryo, and the mixture was extracted for two days. The extract was then concentrated and dried, and dissolved in DMSO to prepare an Izusenryo extract.

[0048] Activity evaluation (bacterial growth inhibition test) For the Penicillium paneum used in Example 1, a bacterial mixed liquid medium was prepared in the same manner as in Example 1, and the bacterial mixed liquid medium was placed in a 96-well plate (96 Well Cell Culture Plate Sterile, Non-pyrogenic Polystyrene: True Line) and a filter (Steradisc 25 0.2 μm γ-ray sterile <s-2502>The above-ground extracts of Izu Senryo filtered through a filter (Kuraray Industries, Ltd.) were mixed to a predetermined concentration. The final concentration of Izu Senryo extract was 500 ppm or 200 ppm. The mixture was cultured at 25°C for 72 hours, and the presence or absence of germination was confirmed visually and under a microscope.

[0049] (result) The results for Penicillium paneum are shown in Table 6 below (a representative result is shown out of n=2 tests). The evaluation criteria were the same as those in Example 1.

[0050] [Table 6]

[0051] Example 5: Activity of Izusenryo Extract against Other Bacteria A fungal growth inhibition test was carried out using the extract of the above-ground parts of C. cerevisiae prepared in Example 4. The wild-type Pichia anomala strain (Pichia) used in Example 2 was used as the test fungus. Pichia cultured on the same fungal agar medium as in Example 1 was collected with a platinum loop and suspended in physiological saline. 6 cfu / ml, which was used as a bacterial solution. A bacterial growth inhibition test was carried out in the same manner as in Example 4, except that the final concentration of the Izusenryo extract was 500 ppm.

[0052] (result) The results for Pichia anomala are shown in Table 7 below (a representative result is shown out of n=2 tests). The evaluation criteria were the same as those in Example 1.

[0053] [Table 7]

[0054] Example 6: Evaluation of the activity of Izusenryo extract on cells Materials and Methods cell culture Human skin fibroblasts (NB1RGB, obtained from Riken) or human keratinocyte cells (HaCaT) were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St Louis, MO, USA) containing 5% FBS (fetal bovine serum), 100 units / ml penicillin, and 100 μg / ml streptomycin (Fujifilm Wako Pure Chemical Industries, Ltd.) at 5% CO2 and 37°C.

[0055] Sample exposure Using the above culture method, 1 × 10 5 The cells were seeded at 10 cells / well, and 24 hours later, a mixture of 2 μL of the sample and 2 mL of DMEM containing 5% FBS, 100 units / ml penicillin, and 100 μg / ml streptomycin was prepared and replaced with the culture medium. The sample used was the Sorghum extract 2 prepared in Example 1. 18 hours later, TRI Reagent was added to the culture medium. TM The cells were lysed using a PBS (Cosmo Bio Co., Ltd.).

[0056] Activity evaluation (Real-time RT-PCR Analysis) Total RNA was extracted and purified from the cells lysed as described above according to the procedure of the SV Total RNA Isolation System (Promega, Fitchburg, WI, USA). TM cDNA synthesis was performed using RT Master Mix (TaKaRa) according to the manufacturer's protocol. Real-time RT-PCR (CFX Connect) was performed using SYBR Green Supermix (Bio-Rad). TM (Bio-Rad, Hercules, CA, USA)) was performed according to the manufacturer's protocol. Analysis was performed using CFX Manager Software. 18s cDNA was used as an internal standard to evaluate the expression levels of SOD1 / 18s, FN3K / 18s, and NRF2 / 18s in HaCaT cells, and NRF2 / 18s and HAS2 / 18s in fibroblast cells. Primers with the following sequences designed using the Primer3 website were used. The expression level in the test group not treated with Sorghum extract was set at 1, and the relative expression level was calculated.

[0057] <Internal standard> 18s: CCGCAGCTAGGAATAATGGA (SEQ ID NO: 1) and CCCTCTTAATCATGGCCTCA (SEQ ID NO: 2) <Target gene> FN3K: CAACCAGAAGCTCAGGGAGAA (SEQ ID NO: 3) and GCTCAGCACCCTCACCTCTT (SEQ ID NO: 4) NRF2: GAAAATGACAAAAGCCTTCACC (SEQ ID NO: 5) and TTGGGAACAAGGAAAACATTG (SEQ ID NO: 6) HAS2: GGCCATTTTCAGAATCCAAA (SEQ ID NO: 7) and GCCTGCCACACTTATTGATG (SEQ ID NO: 8) SOD1: TGGCCGATGTGTCTATTGAA (SEQ ID NO: 9) and ACCTTTGCCCAAGTCATCTG (SEQ ID NO: 10)

[0058] (result) The gene expression levels of SOD1, FN3K, and NRF2 in HaCaT cells treated with Sorghum extract are shown in Figures 1A-C, respectively (a representative example of two tests is shown). As shown in Figures 1A-C, the gene expression levels of SOD1, FN3K, and NRF2 were increased by treatment with Sorghum extract.

[0059] Furthermore, the gene expression levels of NRF2 and HAS2 in fibroblasts treated with Sorghum extract are shown in Figures 2A-B, respectively (a representative example of two tests is shown). As shown in Figures 2A-B, the gene expression levels of NRF2 and HAS2 were increased by treatment with Sorghum extract.

[0060] The present invention includes the following embodiments. (1) An antifungal agent containing an extract of a plant of the Primula family. (2) The antifungal agent according to (1), which is an antifungal agent against at least one fungus selected from the group consisting of the genera Penicillium, Candida, and Pichia. (3) Antioxidants, including extracts of Primula family plants. (4) A desaccharifying agent comprising an extract of a Primula family plant. (5) An agent for promoting the expression of hyaluronic acid synthase genes, comprising an extract of a plant of the Primula family. (6) An agent for promoting the expression of at least one gene selected from the group consisting of SOD1, FN3K, NRF2, and HAS2, comprising an extract of a plant of the Primulaceae family. (7) A cosmetic composition comprising an extract of a Primulaceae plant, or the antifungal agent, antioxidant, deglycosylating agent, or gene expression promoter according to any one of (1) to (6). (8) The antifungal agent, antioxidant, deglycosylating agent, gene expression promoter, or cosmetic composition according to any one of (1) to (7), wherein the Primulaceae plant is a plant belonging to the genus Lycoris or the genus Polytrichum. (9) The antifungal agent, antioxidant, deglycosylating agent, gene expression promoter, or cosmetic composition according to (8), wherein the Primulaceae plant is Trichosanthes or Trichosanthes gracilis.

Claims

1. A composition for promoting gene expression, comprising an extract of sorghum, which promotes the expression of a target hyaluronic acid synthase gene.

2. The composition for promoting gene expression described in claim 1, wherein the hyaluronic acid synthase gene includes the HAS2 gene and promotes hyaluronic acid synthesis in a subject.

3. A composition for promoting gene expression as described in claim 1 or 2, which further promotes the expression of a gene related to the antioxidant effect of a subject, has an antioxidant promoting effect in a subject, and the gene related to the antioxidant effect is the SOD1 gene or the NRF2 gene.

4. The gene expression promoting composition according to any one of claims 1 to 3, which further promotes expression of a gene associated with deglycation in a subject, has a deglycation promoting effect in a subject, and the gene associated with deglycation is an FN3K gene.

Citation Information

Patent Citations

  • Insecticide

    JP2001348305A

  • Expression promoter for active oxygen eliminating enzyme

    JP2007326799A

  • External preparation for skin, humectant, Anti-ageing agent, antioxidant, Anti-inflammatory agent, bleaching agent, and slimming agent

    JP2008231016A

  • Composition for promoting generation of hyaluronic acid containing dandelion extract, and use thereof

    JP2016088939A